Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a price target of $7.

December 18, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst maintains an Overweight rating and a $7 price target for Taysha Gene Therapies.
The reiteration of an Overweight rating by a reputable analyst like Kristen Kluska could instill confidence in investors and potentially lead to a positive short term impact on TSHA's stock price. The maintained price target of $7 suggests the analyst's continued belief in the company's value proposition and growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100